C1858T Polymorphism of Protein Tyrosine Phosphatase Non-receptor Type 22 (PTPN22): an eligible target for prevention of type 1 diabetes?. (4th March 2017)

• Record Type: Journal Article
• Authors: Prezioso, Giovanni; Comegna, Laura; Di Giulio, Concetta; Franchini, Simone; Chiarelli, Francesco; Blasetti, Annalisa
• Is Part Of: Expert review of clinical immunology. Volume 13:Number 3(2017)
• Page Start: 189
• Page End: 196
• Publication Date: 2017-03-04
• Subjects: Ptpn22 -- type 1 diabetes -- autoimmune diseases -- lyp protein -- prevention -- polimorphism -- experimental pharmacology -- autoantibodies; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1080/1744666X.2017.1266257
• Languages: English
• ISSNs: 1744-666X

Abstract

ABSTRACT: Introduction : In type 1 diabetes (T1D), several genetic factors are associated to β-cell autoimmunity onset and clinical progression. HLA-genes play a major role in susceptibility and initiation of β-cell autoimmunity, whereas non-HLA genes may influence the destruction rate. Areas covered : Our review focuses on the possible role of the PTPN22 C1858 T variant as a prognostic factor, given its influence on disease variability. Moreover, we present the potential role of C1858 T as a target for tertiary prevention trials and new therapeutic strategies, such as the LYP inhibitors. We used PubMed for literature research; key words were 'PTPN22', 'C1858 T polymorphism', 'lymphoid-specific tyrosine phosphatase' and 'type 1 diabetes'. We selected publications between 2000 and 2016. Expert commentary : Current data suggest that PTPN22 can be a promising target for therapeutic interventions and identification of at-risk subjects in autoimmune diseases such as T1D.